Development of Selective TLR7 Agonist ADC for Tumor Localized Immunomodulation

Time: 5:30 pm
day: Day Two


  • Discuss the design of a novel and selective TLR7 agonist
  • Learn how Her2-TLR7a ADC activity requires Her2 and TLR7 targeting
  • Explore how anti-HER2-TLR7a ADC induce robust, target dependent activation of the immune system leading to robust anti-tumor responses in vivo